EICHOR
● Not Yet Recruiting
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
Condition: Uterine Endometrial Cancer · Sponsor: Tubulis GmbH
About this study
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with recurrent or progressive uterine endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor therapy. The primary objectives of Phase 1 of this study are to determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). The primary objective of Phase 2 of this study is to evaluate the efficacy of TUB-040 monotherapy at the RP2D in endometrial cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Tubulis Clinical Trial Inquiries · +49 175 800 5594 · ct-inquiries@tubulis.com
Always discuss trial participation with your own doctor first.
Locations (4)
| START Los Angeles | Los Angeles, California, United States | — |
| START New Jersey | East Brunswick, New Jersey, United States | — |
| START New York-Long Island | Lake Success, New York, United States | — |
| START Mountain Region, LLC | West Valley City, Utah, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07743541